The Pharma Solutions (PPS) division of Piramal Pharma Limited, a contract research, development and manufacturing (CDMO) company, announced that the company has made an investment of millions of dollars to build a world-class, high throughput screening facility that will expand the existing in vitro biology capabilities at its drug discovery services facility in Ahmedabad, India.
This new expansion, which is expected to go live in the third quarter of 2022, will significantly expand the primary and secondary screening capabilities of the compounds produced at the Ahmedabad site, the statement said.
The benefits of this new investment will be seen in an improved experience for PPS Discovery Services customers. With the integrated chemistry and biology services now available from a single location, we expect significant improvements in drug discovery cycle times, the company said.
In addition, the on-site team will be expanded to include new employees with experience in the field of biological services, who will complement the existing technical and operational expertise.
Peter DeYoung , Chief Executive Officer, Piramal Pharma Solutions , said, “Supporting customers in the research process is synergistic with our efforts to be a patient-centric CDMO. With this investment, we are expanding our research platform by adding new in vitro biological services to our existing capabilities, making us a more integrated partner. “
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.